Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data
JA Pasco, SE Lane, SL Brennan, EN Timney, G Bucki-Smith, AG Dobbins, GC Nicholson, MA Kotowicz
OSTEOPOROSIS INTERNATIONAL | SPRINGER LONDON LTD | Published : 2014
SUMMARY: We explored the effect of using male and female reference data in a male sample to categorise areal bone mineral density (BMD). Using male reference data, a large proportion of fractures arose from osteopenia, whereas using female reference data shifted the fracture burden into normal BMD. INTRODUCTION: The purpose of this study was to describe fracture risk associated with osteopenia and osteoporosis in older men, defined by areal BMD and using cut-points derived from male and female reference data. METHODS: As part of the Geelong Osteoporosis Study, we followed 619 men aged 60-93 years after BMD assessments (performed 2001-2006) until 2010, fracture, death or emigration. Post-base..View full abstract
Related Projects (2)
Awarded by National Health and Medical Council
Awarded by NHMRC
The study was funded by grants from the National Health and Medical Council (NHMRC 299831, 628582), The University of Melbourne Research Grant Scheme, American Society for Bone and Mineral Research (ASBMR), Perpetual Trustees, Amgen and the Geelong Region Medical Research Foundation, but they played no part in the design or conduct of the study; collection, management, analysis and interpretation of the data; or in preparation, review or approval of the manuscript. JAP was a recipient of the grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation, Arthritis Foundation of Australia and Amgen (Europe) GmBH. SLB was supported by NHMRC scholarship (#519404) and NHMRC Postdoctoral (Training) Fellowship (#1012472). GCN was a recipient of grants from the NHMRC (projects #251638, #299831, #628582) and Amgen (Europe) GmBH. MAK was a recipient of grants from the NHMRC (projects #251638, #299831, #628582), Geelong Regional Medical Research Foundation and Amgen (Europe) GmBH.